QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.87−0.34 (-3.33%)
Close on Nov 17, 2026Market cap $676.84MP/E –Yield –
QuidelOrtho cash
Cash and short-term investments held at the end of each period.
QuidelOrtho's cash was $166.40M at Sep 27, 2026. For fiscal 2025 it was $169.80M, up 72.4% from the year before. The highest annual figure on record is $828.50M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $169.80M | +72.4% |
| FY2024 | Dec 29, 2024 | $98.50M | -41.3% |
| FY2023 | Dec 31, 2023 | $167.90M | -51.5% |
| FY2022 | Jan 1, 2023 | $346.00M | -58.2% |
| FY2021 | Jan 2, 2022 | $828.50M | +69.1% |
| FY2020 | Jan 3, 2021 | $489.90M | +827.8% |
| FY2019 | Dec 29, 2019 | $52.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $166.40M | +69.6% |
| Q2 FY2026 | Jun 28, 2026 | $123.40M | -18.7% |
| Q1 FY2026 | Mar 29, 2026 | $140.40M | +10.4% |
| Q4 FY2025 | Dec 28, 2025 | $169.80M | +72.4% |
| Q3 FY2025 | Sep 28, 2025 | $98.10M | -31.9% |
| Q2 FY2025 | Jun 29, 2025 | $151.70M | +41.1% |
| Q1 FY2025 | Mar 30, 2025 | $127.20M | +61.0% |
| Q4 FY2024 | Dec 29, 2024 | $98.50M | -41.3% |
| Q3 FY2024 | Sep 29, 2024 | $144.00M | -25.7% |
| Q2 FY2024 | Jun 30, 2024 | $107.50M | -52.2% |
| Q1 FY2024 | Mar 31, 2024 | $79.00M | -80.1% |
| Q4 FY2023 | Dec 31, 2023 | $167.90M | -51.5% |
| Q3 FY2023 | Oct 1, 2023 | $193.80M | -26.9% |
| Q2 FY2023 | Jul 2, 2023 | $224.70M | -48.1% |
| Q1 FY2023 | Apr 2, 2023 | $397.70M | -68.8% |
| Q4 FY2022 | Jan 1, 2023 | $346.00M | -58.2% |
| Q3 FY2022 | Oct 2, 2022 | $265.00M | -54.2% |
| Q2 FY2022 | Jul 3, 2022 | $433.10M | -27.0% |
| Q1 FY2022 | Apr 3, 2022 | $1.28B | +160.4% |
| Q4 FY2021 | Jan 2, 2022 | $828.50M | +1469.1% |
| Q3 FY2021 | Oct 3, 2021 | $578.40M | – |
| Q2 FY2021 | Jul 4, 2021 | $593.20M | – |
| Q4 FY2020 | Jan 3, 2021 | $489.90M | – |
| Q4 FY2019 | Dec 29, 2019 | $52.80M | – |
See a number that looks wrong?